DMDianne B. McKay

Dianne B. McKay

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dianne B. McKay has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Alana Shigeoka

    Scripps Clinic and Green Hospital, La Jolla, CA, USA

    3 shared publications
  • Michelle A. Josephson

    Department of Immunology, The Scripps Research Institute, La Jolla, California; and †Section of Nephrology, Department of Medicine, University of Chicago, Chicago, Illinois

    3 shared publications
  • Alana A Shigeoka

    Department of Immunology and Microbial Sciences, The Scripps Research Institute, La Jolla, CA 92037, USA

    2 shared publications
  • Alana Hawkes

    Department of Immunology and Microbiology, Scripps Research, 10550 N. Torrey Pines Rd, La Jolla, CA 92037, United States of America

    2 shared publications
  • Amanpreet Kambo

    Department of Immunology and Microbial Sciences, The Scripps Research Institute , La Jolla, CA 9203

    2 shared publications
  • Andrew J. King

    Division of Nephrology, Department of Medicine, Scripps Clinic and Green Hospital , La Jolla, CA 9203

    2 shared publications

Latest Publications

  • CD14 blockade to prevent ischemic injury to donor organs

    by Jason Own, Richard Ulevitch, Dianne McKay


  • Blockade of T cell activation induced by the simultaneous absence of Nod1 and Nod2 is bypassed by TLR2 signals

    by Sashi Kasimsetty, Alana Hawkes, Sean E. DeWolf, Alexander Welch, Dianne B. McKay


  • TLR2 and NODs1 and 2 cooperate in inflammatory responses associated with renal ischemia reperfusion injury

    by Sashi G. Kasimsetty, Alana Hawkes, Kayvan Barekatain, Elizabeth Soo, Alexander K. Welch, Dianne B. McKay


  • Optimizing organs for transplantation; advancements in perfusion and preservation methods

    by Elizabeth Soo, Christopher Marsh, Robert Steiner, Lisa Stocks, Dianne B. McKay


    • 19 February 2019
      • Vol. 4  (1)

    Pro-Inflammatory Milieu in Human Kidney Perfusates Treated with Hypothermic Pulsatile Machine Perfusion

    by Emmett Ratigan, Sashi Kasimsetty, Jeffrey Cohen, Alana Shigeoka, Lisa Stocks, Kristin Mekeel, Robert Steiner, Dianne B. McKay

    Hypothermic Machine Perfusion (HMP) has been shown to decrease Delayed Graft Function (DGF) and improve outcomes of deceased donor kidney transplants. Although the mechanisms of protection afforded by HMP have not yet been defined, this study tested the hypothesis that HMP improves transplant outcomes by clearing pro-inflammatory molecules from the allograft during pumping. Here we report on 26 allografts preserved via pulsatile HMP at our organ procurement organization that were prospectively evaluated for the time-dependent clearance of cytokines, chemokines and injury markers during their time on pump. Of the cytokines and chemokines measured, IL-1RA, IL-6, IL-18, INFγ, and MCP-1 were increased in the pump perfusate over time and were correlated with markers of kidney injury. Over time on pump, the ‘Danger’ molecule HMGB1 appeared in the perfusate, and perfusate samples activated T-cells ex vivo. The data from this prospective study show that HMP is associated with a time-dependent clearance of pro-inflammatory cytokines, chemokines and danger molecules from donor allografts during the process of pumping, which may in part explain the beneficial effects of HMP.

  • The role of innate immunity in donor organ procurement

    by Dianne B. McKay

    Solid organ transplantation is a life saving procedure for patients with end-stage organ disease, and great care is taken to ensure that healthy organs are procured from deceased or live donors. Despite rigorous efforts to avoid injury, all organs experience some degree of damage from a process called ischemia reperfusion injury (IRI). The first part of the injury (ischemia) occurs when the donor organ's blood supply is compromised, and the second part (reperfusion) occurs when the blood supply is reestablished. The pathophysiology of the IRI is complex, but data from many laboratories have demonstrated that the inciting events of ischemia/reperfusion injury are triggered through a phylogenetically conserved system called the innate immune system. The innate immune system is a complex array of molecules, receptors and cellular elements present in species as diverse as plants to humans. This review discusses the role of the innate immune system in renal IRI and focuses on mechanisms of injury during organ procurement and transplantation. Although there are overlapping complex mechanisms, blockade of the innate immune system will likely provide a novel approach to preventing the earliest events associated with renal ischemia. Potentially, blockade of innate immune activation will provide the opportunity to increase the use marginal donors, especially those from patients deceased after cardiac death.


  • Intracellular Pattern Recognition Receptors and Renal Ischemia

    by Dianne B. McKay

    Renal ischemia is a common cause of acute kidney injury in hospitalized patients. In certain settings renal ischemia is unavoidable, such as in kidneys harvested for transplantation. The molecular and cellular mechanisms that lead to the syndrome of ischemic renal injury are complicated and involve multiple cell types within the kidney, including renal epithelium and vasculature. Although it has been difficult to define pharmacologic targets for AKI, emerging information about a newly discovered host defense system is providing hope for novel pharmacologic targets to prevent and treat AKI. Molecular initiators of damage associated with hypoxia involve a phylogenically conserved host defense system called the innate immune system. Data point to an essential role for receptors of the innate immune system, particularly the membrane-bound Toll-like receptors and the intracellular nucleotide-binding oligomerization domain-like receptors. These receptors have been identified in human and rodent kidneys, and many investigators have shown that their deletion protects from experimental ischemia/reperfusion injury (a model for ischemic acute kidney injury). This review details current information about the innate immune system and the ischemic kidney with a focus on the emerging role of intracellular innate immune receptors.


  • An Inflammasome-Independent Role for Epithelial-Expressed Nlrp3 in Renal Ischemia-Reperfusion Injury

    by Alana A Shigeoka, James L. Mueller, Amanpreet Kambo, John C. Mathison, Andrew J. King, Wesley F. Hall, Jean da Silva Correia, Richard J. Ulevitch, Hal M. Hoffman, Dianne B. McKay

    Cytoplasmic innate immune receptors are important therapeutic targets for diseases associated with overproduction of proinflammatory cytokines. One cytoplasmic receptor complex, the Nlrp3 inflammasome, responds to an extensive array of molecules associated with cellular stress. Under normal conditions, Nlrp3 is autorepressed, but in the presence of its ligands, it oligomerizes, recruits apoptosis-associated speck-like protein containing a caspase recruitment domain (Asc), and triggers caspase 1 activation and the maturation of proinflammatory cytokines such as IL-1β and IL-18. Because ischemic tissue injury provides a potential source for Nlrp3 ligands, our study compared and contrasted the effects of renal ischemia in wild-type mice and mice deficient in components of the Nlrp3 inflammasome (Nlrp3−/− and Asc−/− mice). To examine the role of the inflammasome in renal ischemia-reperfusion injury (IRI) we also tested its downstream targets caspase 1, IL-1β, and IL-18. Both Nlrp3 and Asc were highly expressed in renal tubular epithelium of humans and mice, and the absence of Nlrp3, but not Asc or the downstream inflammasome targets, dramatically protected from kidney IRI. We conclude that Nlrp3 contributes to renal IRI by a direct effect on renal tubular epithelium and that this effect is independent of inflammasome-induced proinflammatory cytokine production.


  • Open Access

    Nod1 and Nod2 Are Expressed in Human and Murine Renal Tubular Epithelial Cells and Participate in Renal Ischemia Reperfusion Injury

    by Alana A Shigeoka, Amanpreet Kambo, John C. Mathison, Andrew J. King, Wesley F. Hall, Jean da Silva Correia, Richard J. Ulevitch, Dianne B. McKay

    Nucleotide-binding oligomerization domain (Nod) 1 and Nod2 are members of a family of intracellular innate sensors that participate in innate immune responses to pathogens and molecules released during the course of tissue injury, including injury induced by ischemia. Ischemic injury to the kidney is characterized by renal tubular epithelial apoptosis and inflammation. Among the best studied intracellular innate immune receptors known to contribute to apoptosis and inflammation are Nod1 and Nod2. Our study compared and contrasted the effects of renal ischemia in wild-type mice and mice deficient in Nod1, Nod2, Nod(1 × 2), and in their downstream signaling molecule receptor-interacting protein 2. We found that Nod1 and Nod2 were present in renal tubular epithelial cells in both mouse and human kidneys and that the absence of these receptors in mice resulted in protection from kidney ischemia reperfusion injury. Significant protection from kidney injury was seen with a deficiency of Nod2 and receptor-interacting protein 2, and the simultaneous deficiency of Nod1 and Nod2 provided even greater protection. We conclude that the intracellular sensors Nod1 and Nod2 play an important role in the pathogenesis of acute ischemic injury of the kidney, although possibly through different mechanisms.